Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation.

@article{Thacker2010UseOO,
  title={Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation.},
  author={Deepika Thacker and Akash Patel and Kathryn M Dodds and David Goldberg and Edisio J. Semeao and Jack Rychik},
  journal={The Annals of thoracic surgery},
  year={2010},
  volume={89 3},
  pages={837-42}
}
BACKGROUND Intestinal inflammation is a component of the pathophysiology of protein-losing enteropathy after the Fontan operation. Oral controlled-release budesonide is 90% metabolized at first pass through the liver, has high enteric anti-inflammatory activity and relatively low systemic effects, and may be an ideal agent for use in treating this disease. METHODS Budesonide was administered to 9 patients (4 male) with protein-losing enteropathy after the Fontan operation. The median interval… CONTINUE READING
27 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…